Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 7c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of ($0.54), $0.07 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $172.3 million versus the consensus estimate of $161.36 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Kite Realty sells City Center in White Plains for $50 million
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance